Gregg Schneider has been at Otsuka for 15 years managing the US R&D financial plan. As part of a larger global organization, the role involves integrating the US R&D financial plan into the parent company's Japanese P&L, requiring close collaboration with Japanese collegues in Tokyo and Osaka.
Educational background in liberal arts. Working in pharma industry, first as medical writer then as pharma project manager since 2000. Have supported numerous submissions and launches in US, EU and Japan. Strong expertise in portfolio management and decision analytics.
• 10 years experience across product development strategy & new product planning, regulatory affairs, business development • Director, BD and Market Research, Nodality • Regulatory Team Leader, Genentech • Engagement Manager, McKinsey • A.B., Biology and Public Policy, Harvard • M.D., Yale
Vladimir has BS & MS in EE & CS, MS in Applied Mathematics, and Ph.D. in Engineering. He contributed to many industries biotechnology, data storages, water resources, telecommunications. Dr. Shnaydman published more than 50 papers. He is co-author of three books.
Description
This symposium will focus on issues surrounding a drug's development life cycle, the use of simulation modeling to enhance development strategy and portfolio decision making, as well as new approaches in portfolio risk assessment and mitigation.
Learning Objectives: Identify processes to generate a list of potential development pathways Recognize how simulation models can enhance development strategy and portfolio decision making Analyze new approaches in portfolio risk assessment and mitigation.